APEIRON Announces Collaboration with Lead Discovery Center GmbH
September 19, 2018 04:00 ET
|
APEIRON Biologics AG
Alliance for medicinal chemistry optimization and development of novel checkpoint blockade approach VIENNA, Austria, Sept. 19, 2018 (GLOBE NEWSWIRE) -- APEIRON Biologics AG, an Austrian company...
APEIRON Appoints Peter Llewellyn-Davies as Chief Executive Officer
July 17, 2018 06:00 ET
|
APEIRON Biologics AG
The Former CEO, Dr. Hans Loibner, Will Continue to Support the Company as Senior Advisor VIENNA, Austria, July 17, 2018 (GLOBE NEWSWIRE) -- APEIRON Biologics AG, a company focused on cancer...
APEIRON, the Medical University of Vienna and the Institute of Molecular Biotechnology Sign Licensing Agreement for a New Checkpoint Inhibitor
June 29, 2018 07:30 ET
|
APEIRON Biologics AG
APEIRON strengthens its proprietary Cbl-b portfolio with cutting edge immunotherapy technology developed at IMBA VIENNA, Austria, June 29, 2018 (GLOBE NEWSWIRE) -- APEIRON Biologics AG, a company...
APEIRON to Present Clinical Data on Two Immunotherapy Programs at the 2018 ASCO Annual Meeting
May 30, 2018 08:27 ET
|
APEIRON Biologics AG
VIENNA, Austria, May 30, 2018 (GLOBE NEWSWIRE) -- APEIRON Biologics AG, a company focused on cancer immunotherapy, today announced it would present data on two of its key programs in three poster...
APEIRON and Evotec Achieve First Milestone in Immuno-oncology Alliance with Sanofi
January 08, 2018 03:02 ET
|
APEIRON Biologics AG
VIENNA, Austria and HAMBURG, Germany, Jan. 08, 2018 (GLOBE NEWSWIRE) -- APEIRON Biologics AG, a company focused on cancer immunotherapy, and Evotec AG (Frankfurt Stock Exchange:EVT) (TecDAX)...
APEIRON to Present at the Biotech Showcase™ Annual Conference on January 9, 2018
January 05, 2018 09:30 ET
|
APEIRON Biologics AG
VIENNA, Austria, Jan. 05, 2018 (GLOBE NEWSWIRE) -- APEIRON Biologics AG, a company focused on cancer immunotherapy, today announced that it will present at Biotech Showcase™ 2018, to be held January...
Apeiron Announces Publication of Clinical Data with Anti-GD2 Antibody Demonstrating Efficacy in Relapsed & Refractory High-Risk Neuroblastoma
December 18, 2017 03:00 ET
|
APEIRON Biologics AG
VIENNA, Austria, Dec. 18, 2017 (GLOBE NEWSWIRE) -- APEIRON Biologics AG, a company focused on cancer immunotherapy, today announced the publication of a successful clinical study in high-risk...